What’s Next After Moderna Sees Good Earnings And Pushes Higher?
Moderna Inc (NASDAQ: MRNA) shares traded higher Thursday after the company reported better-than-expected earnings per share and sales results.
CVS Health Stops Administration Of JNJ COVID-19 Shot In Several Locations: CNBC
Drugstore chain CVS Health Corporation (NYSE:CVS) is no longer offering Johnson & Johnson’s (NYSE:JNJ) COVID-19 vaccine in many of its retail locations, the…
Moderna COVID-19 Shot Is 93% Effective After Six Months Of Second Dose
Moderna Inc’s (NASDAQ:MRNA) COVID-19 vaccine continues to be 93% effective six months after the second dose, the Company reported in…
Delta, Lambda COVID Variants Still Weighing On Market Despite Positive Earnings Reports
The market is still in a waiting mode, with a lot hinging on tomorrow’s jobs report.
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 159 companies achieved new highs for the year.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Moderna Sold Less Than Expected mRNA COVID-19 Vaccine Jabs In Q2; Sees $20B In FY21 Product Sales
Moderna Inc (NASDAQ:MRNA) reports Q2 EPS of $6.46, a turnaround from EPS loss of $(0.31) a year ago, beating the…
Recap: Moderna Q2 Earnings
Shares of Moderna (NASDAQ:MRNA) fell 0.4% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 2183.87% over the past year to $6.46, which beat the estimate of $6.04.